[HTML][HTML] A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN Levine, C Gu, HA Liebman, CP Escalante… - Journal of Thrombosis …, 2012 - Elsevier
Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
[引用][C] A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN LEVINE, C Gu, HA LIEBMAN… - Journal of Thrombosis …, 2012 - elibrary.ru
[HTML][HTML] A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN LEVINE, C GU, HA LIEBMAN… - Journal of Thrombosis …, 2012 - jthjournal.org
Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN Levine, C Gu, HA Liebman… - Journal of …, 2012 - mdanderson.elsevierpure.com
Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN Levine, C Gu, HA Liebman… - … of thrombosis and …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring. Objectives …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring. Objectives …
[引用][C] A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN LEVINE, C GU, HA LIEBMAN… - Journal of Thrombosis …, 2012 - cir.nii.ac.jp
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with
metastatic cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
metastatic cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN LEVINE, C GU, HA LIEBMAN… - … of Thrombosis and …, 2012 - Wiley Online Library
Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
MN Levine, C Gu, HA Liebman… - … of Thrombosis and …, 2012 - europepmc.org
Background Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring. Objectives …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring. Objectives …
[PDF][PDF] A randomized phase II trial of Apixaban for the prevention of thromboembolism in patients with metastatic cancer
H Liebman, C Escalante, S Solymoss - Journal of Thrombosis and …, 2012 - Citeseer
Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring …